2nd Quarter - Report
JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.
Client
Income
—
Expenses
$640,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues related to the regulation of cannabis and CBD Research and development of cannabis-derived therapies Provisions related to patient safety, CBD product regulations and FDA regulation/enforcement Drug safety, prescription drug abuse and drug pricing SAFE Banking Act 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK BOLTON New | — |
| KARAS GROSS | — |
| VIRGINIA MCMILLIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.